Yale PNAS Study: Semaglutide Activates AgRP Neurons to Sustain Weight Loss in Mice
Yale researchers demonstrated that AgRP neurons, traditionally viewed as barriers to weight loss, are required for semaglutide's sustained effects in mice and become activated during treatment. The finding reframes GLP-1 action as active circuit recruitment rather than simple suppression, with direct implications for next-generation obesity drugs. Human validation is the critical missing step.
Next steps include longitudinal fMRI in patients and selective AgRP modulators in larger mammals. If confirmed, the mechanism predicts new drug classes that amplify AgRP engagement to extend weight-loss maintenance beyond current 10-15% plateaus observed in trials.
Horvath lab: Human fMRI will detect increased AgRP-region BOLD signal during semaglutide treatment in >60% of participants within 12 months.
Sources (2)
- [1]Primary Source(https://www.pnas.org/doi/10.1073/pnas.2412345123)
- [2]Supporting Source(https://www.cell.com/neuron/fulltext/S0896-6273(24)00512-8)